Literature DB >> 27974359

Safety and mid-term outcome of catheter ablation of ventricular tachycardia in octogenarians.

Antonio Frontera1, Sandeep Panniker2, Alexander Breitenstein3, Vito Domenico Bruno1, Georgia May Connolly1, David Wilson1, Teresa Rio3, Mehul B Dhinoja3, Wajid Hussain2, Richard J Schilling3, Glyn Thomas1, Tom Wong2, Ross J Hunter3, Frederic Sacher4, Pierre Jaïs4, Edward Duncan1.   

Abstract

AIMS: Radiofrequency (RF) catheter ablation (CA) is superior to standard medical therapy in controlling recurrent ventricular tachycardia (VT). The majority of procedures have been performed in a middle-aged population. The outcome of VT ablation in the elderly has not been described. METHODS AND
RESULTS: We retrospectively studied the outcome and safety of CA of VT in octogenarians performed in four European centres. The population consisted of patients presenting with recurrent VT refractory to medical therapy. Patients aged over 80 years were compared with younger patients undergoing CA. Clinical characteristics, procedural data, complications, and outcomes were examined. Implantable cardioverter-defibrillator (ICD) therapy data were collected. A total of 54 consecutive octogenarian patients underwent RF CA of VT and represented the study group (42 males, age 82.8 ± 2.7 years) compared with a control group of 104 younger patients (85 males, age 66.7 ± 8.9 years). Mean follow-up was 33 ± 48 months. Implantable cardioverter-defibrillators were present in 81 and 86% of patients, respectively (P = 0.93). Left ventricular ejection fraction was 29% ± 8.2 in octogenarians vs. 34% ± 10.2 in the younger group (P < 0.01). More major complications occurred in octogenarians (18 vs. 2%, P < 0.01). During follow-up, there were more ICD shocks in the octogenarians (28 vs. 15%, P < 0.01). The Kaplan-Meier curve of survival after VT ablation confirms comparable survival rates at 1 year, but the elderly have poor survival in the mid-term. Survival in the elderly post VT ablation is comparable with that in an age-matched cohort with ICDs but no VT storm.
CONCLUSION: Octogenarians undergoing CA of VT have more risk factors, higher risk of complications and ICD shocks, but demonstrate comparable short-term survival rates. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com

Entities:  

Keywords:  Complications; Octogenarians; RF catheter ablation; Ventricular tachycardia

Mesh:

Substances:

Year:  2017        PMID: 27974359     DOI: 10.1093/europace/euw236

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  4 in total

Review 1.  [Current strategies in the treatment of ventricular tachycardia by catheter ablation : A review].

Authors:  S Koenig; A Arya; G Hindricks; B Dinov
Journal:  Herz       Date:  2017-09-07       Impact factor: 1.443

Review 2.  [Catheter ablation of ventricular extrasystoles and ventricular tachycardia in the elderly].

Authors:  Philipp Halbfaß; Karin Nentwich; Kai Sonne; Elena Ene; Franziska Fochler; Andreas Mügge; Bernhard Schieffer; Thomas Deneke
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-02-07

3.  Cardiac stereotactic ablative radiotherapy for control of refractory ventricular tachycardia: initial UK multicentre experience.

Authors:  Justin Lee; Matthew Bates; Ewen Shepherd; Stephen Riley; Michael Henshaw; Peter Metherall; Jim Daniel; Alison Blower; David Scoones; Michele Wilkinson; Neil Richmond; Clifford Robinson; Phillip Cuculich; Geoffrey Hugo; Neil Seller; Ruth McStay; Nicholas Child; Andrew Thornley; Nicholas Kelland; Philip Atherton; Clive Peedell; Matthew Hatton
Journal:  Open Heart       Date:  2021-11

4.  Outcome of catheter ablation in the very elderly-insights from a large matched analysis.

Authors:  Kevin Willy; Gerrit Frommeyer; Dirk G Dechering; Kristina Wasmer; Dennis Höwel; Sarah S Welle; Nils Bögeholz; Christian Ellermann; Julian Wolfes; Benjamin Rath; Patrick R Leitz; Julia Köbe; Philipp S Lange; Patrick Müller; Florian Reinke; Lars Eckardt
Journal:  Clin Cardiol       Date:  2020-08-31       Impact factor: 2.882

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.